Toward Therapeutic Drug Monitoring of Lenalidomide in Hematological Malignancy? Results of an Observational Study of the Exposure-Safety Relationship

• Main Authors: Zaiwei Song (Author), Lan Ma (Author), Li Bao (Author), Yi Ma (Author), Ping Yang (Author), Dan Jiang (Author), Aijun Liu (Author), Lu Zhang (Author), Yan Li (Author), Yinchu Cheng (Author), Fei Dong (Author), Rongsheng Zhao (Author), Hongmei Jing (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Objective: Continuous lenalidomide (LEN) therapy is important to achieve a therapeutic effect in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). However, despite dose adjustment according to kidney function, many patients discontinue LEN therapy because of hematological toxicity....